Vera+Tx_JPM+Jan+2025_vF2.pdf

1、 2025 VERA THERAPEUTICS,INC.J.P.Morgan Healthcare ConferenceJanuary 13,20252 2025 VERA THERAPEUTICS,INC.Forward-looking statementsDisclaimerThis material has been made available to you with the consent of Vera Therapeutics,Inc.(we,us,our,or the Company).Statements in this presentation that are not s

2、tatements of historical fact are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.Such forward-looking statements include,without limitation,atacicepts potential to be a transformational treatment for patients with IgAN and a best-in-class and fir

3、st-in-class therapy,the Companys expectations regarding completing the pivotal Phase 3 ORIGIN 3 trial and the Phase 2 extension study in participants who completed the Phase 2b or Phase 3 ORIGIN trials,atacicepts potential to be a transformational treatment for additional patient cohorts beyond thos

4、e with IgAN,the Companys expectations regarding initiating clinical trials of atacicept for additional indications,the design and management of the Companys clinical trials,expectations regarding reporting results from such clinical trials and regulatory matters,including the timing and likelihood o

5、f success in obtaining drug approvals,atacicepts projected launch and Veras potential research and development plans for VT-109.Words such as“anticipate,”“plan,”“expect,”“will,”“may,”“potential”and similar expressions are intended to identify forward-looking statements,though not all forward-looking

6、 statements necessarily contain these identifying words.These forward-looking statements are based on the beliefs of the Companys management as well as assumptions made by and information currently available to the Company.Such statements reflect the current views of the Company with respect to futu